University Health Network

Miikana Therapeutics, Inc.

Mark R Bray

Jacqueline M Mason

Richard Brokx

Sze-Wan Li

Heinz W Pauls

John S Ward

Xiao-Yi Xiao

Tak Wah Mak

Radoslaw Laufer

Anthony Treston

Grace Ng

Gregory E Agoston

Dinish V Patel

Graham Fletcher

David Hedley

Ines Lohse

Anthony M Treston

David W Hedley

The invention provides novel anti-LILRB3 antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer, autoimmune disease, or allergic inflammation. This invention can also be used to modulate osteoclast differentiation.

LILRB3-binding molecules and uses therefor

Disclosed is Crystal Form S4 of a fumarate salt of compound (I) represented by the following structural formula: (I) The molar ratio between compound (I) and fumaric acid is 1.0:1:0. Crystal Form S4, 5 characterized by an X-ray powder diffraction pattern which comprises peaks at 6.6°, 9.8°, 16.3°, 21.1°, 28.7°, and 30.2°±0.2 in 2θ.

Crystal form S4 of the PLK4 inhibitor (1R,2S)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)-1 h-imidazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3′-indolin]-2′-one fumarate

The invention provides novel anti-FCMR antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.

FCMR-binding molecules and uses thereof

Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula (Formula (I)) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.

Combination therapies for inhibition of polo-like kinase 4

Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula: (I) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.

Combination therapies for inhibition of TTK protein kinase

The invention is a compound represented by Structural Formula (I):  or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).

RIPK2 inhibitors and method of treating cancer with same

The invention is a compound represented by Structural Formula (I): (I); or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I). 

The invention is related to a method of treating a subject with pancreatic cancer with administration of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. 

Treatment for pancreatic cancer

Disclosed are protein kinase inhibitors, compositions comprising such inhibitors, and methods of use thereof. More particularly, disclosed are inhibitors of Aurora A (Aurora-2) protein kinase. Also disclosed are methods of treating diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer.

Growing community of inventors

Oakville, Canada

Mark R Bray